The central task is not “Does this child have one high number?” It is “Was the number valid, what category does it occupy, is the pattern persistent, and what phenotype and risk does it represent?”
Commit before you read
Opening case
A 15-year-old with obesity has a first automated BP of 134/76 mm Hg at a well visit. He feels well. The medical assistant used a cuff that barely encircled the arm.
What is the best next action?
Do not diagnose hypertension—and do not ignore it. Rest the patient, select a correctly sized cuff, repeat at least 2 measurements, average the repeat values, and confirm an elevated oscillometric result by auscultation. Only then classify the visit. A small cuff can artifactually raise BP; an isolated first oscillometric value is a screening signal, not a diagnosis.1
Learning objectives
By the end, the resident can
1
Obtain and classify a defensible pediatric BP by age and technique.
2
Execute the correct follow-up interval for elevated, stage 1, and stage 2 BP.
3
Choose a risk-directed evaluation and recognize secondary-cause clues.
4
Determine ABPM quality, thresholds, phenotype, and dipping using the 2022 scheme.
5
Select lifestyle and first-line drug therapy and identify hypertensive emergency.
01
Measurement is a diagnostic test
Seat quietly for 3–5 minutes; back supported, feet uncrossed and on the floor.
Use the right arm, supported at heart level, uncovered; patient and observer do not talk.
Cuff bladder width at least 40% of mid-arm circumference; length 80%–100%.
An oscillometric device may screen, but suspected elevation requires auscultatory confirmation.
At one visit, repeat an initial high oscillometric reading and average subsequent readings.
Why the right arm? The normative tables are right-arm based, and a left-arm value may be falsely low with coarctation.
02
Classify by age—and by the higher component
Category
Age 1 to <13 years
Age ≥13 years
Normal
<90th percentile
<120/<80
Elevated
≥90th to <95th percentile, or 120/80 to <95th percentile—whichever threshold is lower
120/<80 to 129/<80
Stage 1 HTN
≥95th to <95th percentile + 12 mm Hg, or 130/80–139/89—whichever threshold is lower
130/80–139/89
Stage 2 HTN
≥95th percentile + 12 mm Hg, or ≥140/90—whichever threshold is lower
≥140/90
Systolic and diastolic BP are classified independently; the more severe category controls. Use the full AAP normative tables or a validated implementation—not the simplified screening table—to diagnose a child under 13.1
Measure at every encounter for obesity, renal disease, diabetes, aortic arch obstruction/coarctation, or medications known to raise BP.
Age <3
Measure at well visits when risk exists: prematurity <32 weeks, VLBW/NICU or umbilical arterial line, congenital heart disease, renal/urologic disease, recurrent UTI/hematuria/proteinuria, transplant, malignancy, BP-raising drugs, selected systemic disease, or raised intracranial pressure.
Diagnosis
In the routine outpatient setting, diagnose HTN after auscultatory-confirmed readings in the hypertensive range at 3 different visits (≥95th percentile if <13; ≥130/80 if ≥13). Stage 2 or symptoms accelerate the pathway.
04
Confirm the phenotype with ABPM
ABPM separates a clinic signal from the child’s lived BP exposure. It detects white coat hypertension, masked hypertension, isolated nocturnal hypertension, abnormal dipping, and inadequate treatment coverage.
White coat HTNClinic hypertensive; ambulatory normal
Masked HTNClinic below HTN threshold; ambulatory high
Ambulatory HTNBoth clinic and ambulatory high
Normal BPBoth settings below thresholds
2022 update: BP load is no longer used to classify ABPM phenotypes. Mean 24-hour, wake, and sleep SBP and DBP control the classification; any elevated period/component can make the study abnormal.4
05
Look for the cause—but avoid indiscriminate testing
History and examination should cover perinatal and renal history, medications/substances, sleep, nutrition, activity, psychosocial context, and family history. Check pulses and four-extremity BP when indicated; look for growth failure, syndromic features, abdominal bruit/mass, endocrine clues, and target-organ symptoms.
Streamlined workup rule: A child ≥6 years with family history of HTN, overweight/obesity, and no history or examination clue to a secondary cause does not require an extensive secondary evaluation.1
Medication and substance audit
Ask directly about stimulants, decongestants, caffeine/energy products, NSAIDs, hormonal contraception, glucocorticoids, tricyclics, supplements, amphetamines, and cocaine. “No medications” is not a completed exposure history.
Add hemoglobin A1c, AST/ALT, and fasting lipid panel
History/exam directed
Fasting glucose, TSH, drug screen, polysomnography, CBC, or focused secondary-cause testing
DoObtain echocardiography when pharmacologic treatment is being considered to assess LV mass, geometry, and function.
Do notUse ECG to exclude LVH; it is not recommended for target-organ assessment in pediatric HTN.
07
Treat the child’s risk profile
At elevated BP or HTN diagnosis: DASH-style diet, sodium reduction, healthy sleep, weight management where relevant, and moderate-to-vigorous activity 30–60 minutes on 3–5 days/week.
Medication is indicated after failed lifestyle therapy, particularly with LVH, symptomatic HTN, or stage 2 HTN without a clearly modifiable factor.
Prefer ACE inhibitor or ARB with CKD, proteinuria, or diabetes; monitor creatinine and potassium and address pregnancy potential.
Goal: <90th percentile for children <13; <130/80 mm Hg for adolescents ≥13. In CKD, use ABPM to target 24-hour MAP <50th percentile.
Medication sequencing and follow-up
Start one first-line agent at a low dose. Titrate every 2–4 weeks until controlled, the maximal dose is reached, or adverse effects occur; see the patient every 4–6 weeks during titration. Add a second complementary agent if needed. Apparent resistance requires measurement review, adherence confirmation, removal of BP-raising exposures, reassessment for secondary disease, and ABPM confirmation before labeling true resistant HTN.
08
Recognize urgency before finishing the workup
Stage 2 HTN requires four-extremity assessment and repeat measurement or subspecialty referral within 1 week. If it persists, proceed with ABPM, diagnostic evaluation, and treatment.
Immediate care: stage 2 BP plus symptoms, BP >30 mm Hg above the 95th percentile, or an adolescent BP >180/120 mm Hg. Neurologic change, seizure, visual symptoms, heart failure, chest pain, or acute kidney injury make this a hypertensive emergency until proved otherwise.1
With acute severe HTN and life-threatening symptoms, use short-acting therapy in a monitored setting and reduce no more than 25% of the planned BP reduction in the first 8 hours. Avoid rapid normalization that can cause cerebral, cardiac, or renal ischemia.
Office pathway
What happens after today’s verified BP?
Select the category. The time interval is part of the diagnosis; skipping it either delays care or overdiagnoses transient BP elevation.
The first oscillometric reading is often the highest. Repeat and average.
Using the screening table to diagnose
It is intentionally sensitive. Diagnosis requires the full normative table.
Calling elevated BP “stage 1”
For adolescents, 128/78 is elevated—not stage 1.
Ordering a broad endocrine panel
Start with history, examination, basic renal testing, and targeted clues.
Getting an ECG for LVH
Echo is the recommended assessment when medication is being considered.
Starting medication before ABPM
When feasible outside urgent situations, confirm HTN and phenotype first.
Using home BP to diagnose a phenotype
Home BP can support follow-up after diagnosis, but it does not diagnose HTN, masked HTN, or white coat HTN.
ABPM interpretation lab
Turn 24 hours of readings into a defensible phenotype
Quality first, thresholds second, phenotype third, pattern and clinical meaning last. A colorful report is not an interpretation.
Quality gate
Duration24 h preferred; 18–20 h can be acceptable if sleep is captured
Success≥70% of attempts; usually 40–50 successful readings
DensityAt least 1 valid reading each hour, including sleep
ProgrammingEvery 15–20 min awake; every 20–30 min asleep
DiaryPatient-recorded wake/sleep, medication, activity, and symptoms
Device checkValidated pediatric cuff device; 3 same-arm comparison values within ±5 mm Hg on average
A suboptimal study may still be clinically informative, but ideally should be repeated. Exclude test readings, vigorous-exercise readings, and biologically implausible values; use diary-defined rather than fixed clock periods.4
2022 mean ABPM thresholds
Age
24-hour mean
Wake mean
Sleep mean
≥13 years
Abnormal if SBP ≥125 or DBP ≥75
Abnormal if SBP ≥130 or DBP ≥80
Abnormal if SBP ≥110 or DBP ≥65
<13 years
For each period and component, use the lower of the sex/height-specific pediatric 95th percentile or the adolescent static cutoff above.
Dipping = (mean awake BP − mean sleep BP) ÷ mean awake BP × 100. Normal is usually 10%–20%; <10% is nondipping; a negative value is reverse dipping.
High-yield distinction: Isolated sleep hypertension counts as ambulatory hypertension. Isolated nondipping, with all mean BPs below threshold, generally does not by itself create masked hypertension.4
Branching cases
Make the next decision
Each case forces a sequence: measurement, timing, phenotype, workup, and treatment. Your reasoning log records both correct moves and attractive errors.
Reasoning log
Complete a decision to build your log.
Board-style assessment
Test transfer, not recall alone
Questions mix thresholds, time-to-recheck, ABPM interpretation, diagnostic restraint, treatment, and emergencies. Your first answer is scored; every response receives a teaching explanation. Mastery target: 23/26 (88%).
Question 1 of 26Score: 0
Quick reference
Resident pocket card
Designed for print or a fast pre-clinic review. This is a cognitive aid, not a substitute for the full guideline or local emergency protocols.
Content was reconciled at the statement level. When the 2017 AAP guideline and 2022 AHA ABPM statement differ on ambulatory classification, the newer ABPM statement controls.
1
AAP pediatric hypertension clinical practice guideline
Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904.
Flynn JT, Baker-Smith CM, et al. Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2018;142(3):e20182096.
A 2024 AAP Pediatrics perspective continues to identify the 2017 CPG as the AAP’s current pediatric hypertension guidance while emphasizing evidence gaps in long-term outcomes and lifestyle-treatment targets.